Global Autoimmune Hemolytic Anemia Therapeutics Market is segmented By Drug Class (Corticosteroids, Monoclonal Antibodies, Others), By Route of Administration (Oral, Injectable), By Therapy Type (First Line Therapy, Second Line Therapy, Third Line Therapy), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, E-Pharmacy), By Disease Type (Cold Antibody Hemolytic Anemia, Warm Antibody Hemolytic Anemia), By Treatment (Surgery, Medication), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Report Overview
The Global Autoimmune hemolytic anemia therapeutics Market is expected to grow at a high CAGR during the forecast period (2024-2031).
Autoimmune Hemolytic Anemia (AHA) also known as immune hemolytic anemia is an infrequent red blood cell disorder and occurs when the immune system makes antibodies that attack red blood cells in the body. This reduces the red blood cells counts, causing hemolytic anemia. AHA can result from medication or an underlying disease or can be idiopathic. The key types of AHA include warm antibody hemolytic anemia and cold antibody hemolytic anemia. Some of the treatments for AHA can include splenectomy, corticosteroids such as immunosuppressive drugs, prednisone, and/or blood transfusions.
Autoimmune Hemolytic Anemia Therapeutics Market Summary
|
Metrics |
Details |
|
CAGR |
High |
|
Size Available for Years |
2022-2031 |
|
Forecast Period |
2024-2031 |
|
Data Availability |
Value (US$) |
|
Segments Covered |
Drug Class, Route of Administration, Therapy Type, Distribution Channel, Disease Type, Treatment, and Region |
|
Regions Covered |
North America, Europe, Asia-Pacific, South America and Middle East & Africa |
|
Fastest Growing Region |
Asia-Pacific |
|
Largest Region |
North America |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
For More Insights Request Free Sample
Autoimmune Hemolytic Anemia Therapeutics Market Dynamics
The high cost of therapeutics to treat autoimmune hemolytic anemia has encouraged pharmaceutical companies and governments of various countries to come up with financial assistance programs and reimbursements over the years. Financial assistance programs such as Obamacare in the US have minimized the treatment cost burden on patients. They help in providing the required medicines to patients and increase patient compliance to treatments including monoclonal antibodies such as rituximab. Such a patient assistance program will lead to the expansion of the global Autoimmune hemolytic anemia therapeutics Market at a CAGR of over 9% during the forecast period.
Increasing in financial assistance programs
Because of the high cost of therapeutics, there is a significant increase in the number of financial assistance programs and reimbursements. To reduce the treatment cost burden on patients, governments of various countries and pharmaceutical vendors have introduced various patient assistance programs. Such projects aim to improve the quality of healthcare by providing affordable health insurance. An increase in government initiatives that provide financial assistance will encourage patients to opt for the treatment which increases patient compliance.
Increase in the use of the drug
The growth of the global autoimmune hemolytic anemia therapeutics market is driven by the rising use of drugs such as corticosteroids for patients suffering from AHA. Corticosteroids are widely prescribed to reduce complications such as obesity, diabetes, osteoporosis, and uncontrolled hypertension.
COVID-19 Impact Analysis
COVID-19 pandemic affected the global economy in many terms, such as directly affecting production and demand, supply chain disruption, and financial impact. COVID-19 has directly impacted the manufacturers' supply chain across the globe and shut down the production facilities to minimize the risk of virus spread. Also, the lockdown policies have strengthened the autoimmune hemolytic anemia therapeutics market, as people with the disease are more prone to Covid-19 infection. Despite the pandemic, there is growth in the overall autoimmune haemolytic anaemia therapeutics market and is expected to drive the market size in the global market during the forecast period.
Autoimmune Hemolytic Anemia Therapeutics Market Segment Analysis
Based on the disease type, the Autoimmune hemolytic anemia therapeutics market has been classified into Cold Antibody Hemolytic Anemia and Warm Antibody Hemolytic Anemia.
Cold Antibody Hemolytic Anemia Segment to Offer Significant Opportunities
The cold antibody hemolytic anemia segment accounted for a major share in the global Autoimmune hemolytic anemia therapeutics Market in 2020 and is expected to maintain its dominance by 2027. The larger market share is attributed to a large chunk of the population suffering from cold antibody hemolytic anemia.
Corticosteroids Segment to Account for Major Share of Global Market
Based on drug class, the global Autoimmune hemolytic anemia therapeutics Market can be classified into corticosteroids, monoclonal antibodies, and others. The corticosteroids segment is anticipated to dominate the global market during the forecast period due to an increase in the usage of corticosteroids for the treatment of autoimmune hemolytic anemia.
Autoimmune Hemolytic Anemia Therapeutics Market Geographical Share
Based on geography, the study analyzes the autoimmune hemolytic anemia therapeutics in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.
North America leads the global market throughout the forecast period
North America is a significant market for autoimmune hemolytic anemia therapeutics. The availability of patient assistance programs and regulatory incentives that provide development assistance and financial incentives to pharmaceutical companies for the development of novel drugs is driving market growth in the region. The proven efficacy of targeted therapies is encouraging vendors to conduct extensive research in the area, which will also fuel the growth of the market. With the increasing demand, several vendors have started focusing on developing novel combination therapies for the treatment of autoimmune hemolytic anemia in the region.
Autoimmune Hemolytic Anemia Therapeutics Market Companies
The global autoimmune hemolytic anemia therapeutics market is fragmented in nature comprising a large number of regional players. Some of the players operating in the global market are, Amneal Pharmaceuticals, Inc., Incyte Corp., Kezar Life Sciences, Inc., Rigel Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Sanofi, Pfizer, Inc., Baxter International, Inc., Mylan NV and Teva Pharmaceutical Industries Ltd.
Amneal Pharmaceuticals Inc.
Overview: Amneal Pharmaceuticals Inc. is engaged in the development, promotion, sale, and distribution of proprietary branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including migraine and Parkinson's disease. The company offers Azathioprine, which is an immunosuppressive medication used to treat autoimmune hemolytic anemia
Product Portfolio: The Company’s portfolio comprises generic products and speciality products. Generics business includes manufacturing of oral solids, injectable, ophthalmic, liquids, topical, soft gels, inhalation products. Specialty Pharma business includes products that meet important medical needs in central nervous system disorders, parasitic infections and other therapeutic categories.
Why Purchase the Report?
- Visualize the Autoimmune hemolytic anemia therapeutics market segmentation composition by drug class, disease type, distribution channel, route of administration, treatment, therapy type, and region, highlighting the critical commercial assets and players.
- Identify commercial opportunities in the autoimmune hemolytic anemia therapeutics Market by analyzing trends and co-development deals.
- Excel data sheet with thousands of data points of autoimmune hemolytic anemia therapeutics Market - level 6 segmentation.
- PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
- Product mapping in excel for the key product of all major market players
The Global Autoimmune hemolytic anemia therapeutics Market report would provide access to an approx. 72 market data table, 79 figures and 180 pages.
Target Audience
- Service Providers/ Buyers
- Industry Investors/Investment Bankers
- Education & Research Institutes
- Research Professionals
- Emerging Companies
- Manufacturers
